BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10098948)

  • 1. Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents.
    Shmueli J; Israilov S; Segenreich E; Baniel J; Livne P
    Int J Impot Res; 1999 Feb; 11(1):15-9. PubMed ID: 10098948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 5. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
    Engel JD; McVary KT
    Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.
    Moriel EZ; Rajfer J
    J Urol; 1993 May; 149(5 Pt 2):1299-300. PubMed ID: 8386779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
    Hatzimouratidis K; Hatzichristou DG
    Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atropine role in the pharmacological erection test: study of 228 patients.
    Sogari PR; Telöken C; Souto CA
    J Urol; 1997 Nov; 158(5):1760-3. PubMed ID: 9334595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men.
    Richter S; Vardi Y; Ringel A; Shalev M; Nissenkorn I
    Int J Impot Res; 2001 Jun; 13(3):172-5. PubMed ID: 11525316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endocavernous drug infusions revisited].
    Bellorofonte C; Ruoppolo M; Dell'Acqua S; Zaatar C; Ferri PM; Yamak R; Tagliaferri A; Tombolini P
    Arch Ital Urol Nefrol Androl; 1991 Dec; 63(4):475-9. PubMed ID: 1838835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
    Vardi Y; Lidgi S; Moskovitz B; Levin RD
    Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP; Engel RM; Smolev JK; Brendler CB
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction.
    Purvis K; Egdetveit I; Christiansen E
    Int J Impot Res; 1999 Oct; 11(5):287-99. PubMed ID: 10553808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction.
    Casabé A; Bechara A; Cheliz G; Romano S; Rey H; Fredotovich N
    Int J Impot Res; 1998 Mar; 10(1):5-9. PubMed ID: 9542684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and therapeutic technology assessment. Vasoactive intracavernous pharmacotherapy for impotence: papaverine and phentolamine.
    JAMA; 1990 Aug; 264(6):752-4. PubMed ID: 2374280
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of Alprostadil (Caverject) and a combination of vasoactive drugs as local injections for the treatment of erectile dysfunction.
    Abdallah HM
    Int Urol Nephrol; 1998; 30(5):617-20. PubMed ID: 9934808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Action of vasoactive drugs in male sexual impotence].
    Morales JC; Elizondo B
    Arch Esp Urol; 1989; 42(9):900-4. PubMed ID: 2624491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.